Thread by @MPishvaian

#ASCO21 #PancreaticCancer

📢ASCO is a few days away, and I decided to put together my list of
✅Top Abstracts to watch for

📝I tagged who I could

Starting with my Top Pancreatic Cancer Abstracts...in no particular order.....

(A common theme: NGS and fusion testing is🗝️)

#ASCO21 #PancreaticCancer

@VivekSubbiah, et al (Abstr 3079)
➡️RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors

I know - he has presented this before🙄

🥳but now 3/3 patients with pancreatic cancer responded - one with a CR ongoing at 20.8 months‼️

#ASCO21 #PancreaticCancer

Alison M. Schram, @EileenMOReilly @graokane @benweinbergmd (abstr 3003)
➡️Zenocutuzumab (MCLA-128) in pancreas cancer and other solid tumors harboring NRG1 fusions

✅INV-assessed ORR = 40% (4/10)
✅Tumor regression in 7/10 pts
✅DCR = 90%
✅DOR TBD

#ASCO21 #PancreaticCancer

Funda Meric-Bernstram @Dr_R_Kurzrock & others
(abstr 3004)
➡️My Pathway: Pertuz + trastuz in HER2+ cancers

Yes, also presented before - but now🔬KRAS WT

✅1/3 PDAC pts responded - DOR = 19.3 months‼️

✅(BTW 31% of CRC, and 26% of CCAs responded)

#ASCO21 #PancreaticCancer

Patricia LoRusso and others (abstr 3016)
➡️Phase I study of the MDM2-p53 antagonist BI 907828 in advanced cancer patients

✅Very early study - but 1 uPR in an MDM2 amplified pancreatic cancer patient

🤔MDM2 amp might the next biomarker subgroup

#ASCO21 #PancreaticCancer

2 DDR-Related Abstracts:

JM Romero et al (abstr 2546)
➡️4-chemokine immune-signature in HR-def
✅👓 PDACs with markers of T cell-inflammation

RC Lynch et al (abstr 3006)
➡️Ph I/II of CYT-0851 - an inhib of RAD51-med HR
✅Minor response in 1 PDAC pt

#ASCO21 #PancreaticCancer

MH O'Hara (abstr 4019)
➡️Gem + nab-pac ± nivo ± the CD40 agonist APX005M: Phase 2 final results

✅This one...I need to👀
❓The GA-nivo arm did the best
❓Better than GA-APX
❓And both better than the combo arm

#ASCO21 #PancreaticCancer

J Ezenfis et al (abstr 4018)
➡️Phase 3 of Masitinib plus gemcitabine as first-line treatment of pancreatic cancer with pain
✅Another one to be 👀
mOS for LAPC patients with pain
👉13 mos MAS-GEM
👉11.2 mos PBO-GEM
❗️Small #s in the subgroups though

#ASCO21 #PancreaticCancer

And finally - a couple IO Phase 1 trials to👓
D Liu et al (abstr 2503)
➡️SHR-1701, a bifunctional PD-L1 & TGF-β inh
✅PR in a panc acinar Ca

V Boni (abstr 2513)
➡️Nemvaleukin alfa (synth cytokine, binds to the IL-2R) + pembro
✅PR in 1 of 2 PDAC pts